CureVac

Biotechnology ResearchBaden-württemberg, Germany501-1000 Employees

CureVac is a multinational biotechnology company focused on messenger RNA (mRNA) technology for human medicine. It has developed and refined foundational approaches that supported the production of mRNA vaccines used to address COVID-19 and is pursuing additional therapeutic applications of mRNA in areas with high medical need. The company is pursuing both off-the-shelf and personalized cancer vaccine candidates, as well as prophylactic vaccines and approaches that prompt the body to generate therapeutic proteins, aided by omics and computational tools. Headquartered in Tübingen, Baden-Württemberg, CureVac operates sites in the Netherlands, Belgium, Switzerland, and the United States.

Founded in 2000, it belongs to the biotechnology research sector and maintains an international footprint through its multiple sites. In 2026, CureVac filed a patent-infringement lawsuit against Moderna in Delaware federal court over mRNA vaccine technology.

Sign up for free to view info

Email Format Employee directory